Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Core Scientific (CORZ) Notes Payables (2021 - 2025)

Core Scientific has reported Notes Payables over the past 5 years, most recently at $16.2 million for Q1 2025.

  • Quarterly results put Notes Payables at $16.2 million for Q1 2025, down 30.51% from a year ago — trailing twelve months through Mar 2025 was $16.2 million (down 30.51% YoY), and the annual figure for FY2024 was $16.3 million, down 86.9%.
  • Notes Payables reached $16.2 million in Q1 2025 per CORZ's latest filing, roughly flat from $16.3 million in the prior quarter.
  • Across five years, Notes Payables topped out at $977.6 million in Q3 2022 and bottomed at $16.2 million in Q1 2025.
  • Median Notes Payables over the past 5 years was $35.9 million (2022), compared with a mean of $130.4 million.
  • Peak annual rise in Notes Payables hit 243.13% in 2023, while the deepest fall reached 87.28% in 2023.
  • Over 5 years, Notes Payables stood at $76.0 million in 2021, then plummeted by 52.31% to $36.2 million in 2022, then soared by 243.13% to $124.4 million in 2023, then plummeted by 86.9% to $16.3 million in 2024, then decreased by 0.47% to $16.2 million in 2025.
  • Business Quant data shows Notes Payables for CORZ at $16.2 million in Q1 2025, $16.3 million in Q4 2024, and $17.9 million in Q3 2024.